WuXi Biologics and GSK Ink Licensing Agreement for T-Cell Engaging Antibodies
China-based WuXi Biologics (HKG: 2269) has announced a licensing agreement with GSK plc (NYSE: GSK),...
GSK
GSK Partners with CASPC to Advance HIV Sustained Care Advocacy in China
The 5th China International Import Expo (CIIE) saw the unveiling of a partnership between GlaxoSmithKline...
NMPA Suspends GSK’s Avodart Amid Inspection Findings
The National Medical Products Administration (NMPA) has decided to suspend the import, sales, and use...
Recbio’s Neoadjuvant HPV Vaccine Accepted for Review by NMPA
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced that a clinical trial...
China Approves GSK’s Juluca for HIV-1 Infection
The National Medical Products Administration (NMPA) has approved the market application for GlaxoSmithKline’s (GSK, NYSE:...
Recbio Completes Enrollment for HPV Vaccine REC603 Immuno-Bridging Study
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of subject...
GSK Launches Nucala in China for Eosinophilic Granulomatosis with Polyangiitis
UK pharmaceutical giant GlaxoSmithKline (GSK, LON: GSK, NYSE: GSK) has announced the official market launch...